Investment Analysts’ Recent Ratings Updates for Novo Nordisk A/S (NVO)

Several brokerages have updated their recommendations and price targets on shares of Novo Nordisk A/S (NYSE: NVO) in the last few weeks:

• 8/12/2026 – Novo Nordisk A/S was given a new $47.00 price target by Berenberg Bank.
• 8/12/2026 – Novo Nordisk A/S was downgraded by Berenberg Bank from “buy” to “hold”.
• 8/11/2026 – Novo Nordisk A/S was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/6/2026 – Novo Nordisk A/S had its “market perform” rating reaffirmed by BMO Capital Markets. They now have a $47.00 price target on the stock.
• 8/5/2026 – Novo Nordisk A/S was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 7/20/2026 – Novo Nordisk A/S had its “sell (d+)” rating reaffirmed by Weiss Ratings.
• 7/20/2026 – Novo Nordisk A/S had its “neutral” rating reaffirmed by Citigroup Inc..
• 7/13/2026 – Novo Nordisk A/S was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/6/2026 – Novo Nordisk A/S had its “hold” rating reaffirmed by HSBC Holdings plc.
• 6/20/2026 – Novo Nordisk A/S was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/19/2026 – Novo Nordisk A/S was upgraded by Nordea Equity Research from “hold” to “buy”.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a dividend, which will be paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th will be given a $0.5786 dividend. The ex-dividend date is Monday, August 17th. This represents a dividend yield of 256.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 42.79%.

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.